THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION)

Similar documents
ICMJE Form for Disclosure of Potential Conflicts of Interest

RMI Researched Medicines Industry Association

Toward Patient-Centric Marketing

ICMJE Form for Disclosure of Potential Conflicts of Interest

Ghassan Karam Project Manager ICTRP - WHO, Geneva

Ref: FOI/CAD/ID August Freedom of Information Act 2000

ICMJE Form for Disclosure of Potential Conflicts of Interest

Dec LILLE, France. 7 th. edition. A 360 approach to source early-stage innovations in Life Sciences. Organised by: In collaboration with:

Hospitality and Gifts Register (declared in year)

1 st Regional Conference on Regulatory Harmonisation

DOING THE RIGHT THING AND DOING THINGS RIGHT

Round Table Discussion: Shared Views and Perspectives on Outsourcing

Conflict of Interest Disclosure Form

Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA. Tel: +1 (650)

COPD (quality standard) Stakeholders 3M Health Care UK 5 Boroughs Partnership NHS Foundation Trust AbbVie Academy for Healthcare Science Action on

Australian Biomedical & Healthcare

THE NICHOLAS HALL OTC MARKETING AWARDS 2018

Corporate Press Kit. PageGroup Changes Lives for People through Creating Opportunity to Reach Potential

THE NICHOLAS HALL OTC MARKETING AWARDS 2018

Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project. Chris Chinn VP and Head of RWE

CME Information 2018 AAD SUMMER MEETING DIRECTLY SPONSORED BY THE AMERICAN ACADEMY OF DERMATOLOGY

Latin America: An Evolving Regulatory Environment September 15, Mapi 2015, All Rights Reserved

Statisticians in the Pharmaceutical Industry Limited

CONVERSATIONS PRIMARY CARE

Health and Life Sciences Committee. Advancing the ASEAN Post-2015 Health Development Agenda

Boston University Expert Review Meeting on the Evaluation of Novartis Access

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal (STA)

1st Maghreb Regulatory Conference

Direct Relief. GENERAL INFORMATION Organization Name

NHS Kernow Disclosure Log Freedom of Information Requests May 2015

Internal Audit Resources 2010

Content EUROHEARTCARE ORGANISATION... 3 EUROHEARTCARE FACTS & FIGURES... 4 GENERAL MEETING INFORMATION... 5 INDUSTRY PARTNERS PARTICIPATION...

Santander Latin American Conference. Cancun, January 2009

September 2-3, 2013 Chengdu, China

Atrial Fibrillation (Review) guideline

Physician / Investigator. Over 40% of clinical trial data are entered into health record and EDC 1

FEBRUARY 4 TH, 2017 PROGRAM CHAIRS REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA RESERVE YOUR SPACE TODAY! PLEASE CONTACT:

D Start of quarterly EPAD Cohort recruitment update on EPAD website WP4 EPAD Cohort and EPAD Trials

Patient survey report Survey of people who use community mental health services 2011 Pennine Care NHS Foundation Trust

COUNTRY OVERALL COMPARATIVE SIZE

00 Telefónica in Telefónica is a world leader in the telecommunications sector, with over 154 million accesses and presence in 19 countries

# $ pages In Stock. Report Description

Web and Video Conferencing Trends in the NHS

Ontario Public Drug Programs

Our Commitment to Deliver our Science to Patients

Real World Evidence in Europe

Chronic kidney disease (update) Stakeholders

Regional Round Table Event. Presentation Materials

INDUSTRY OVERVIEW RESEARCH COMPANY PROFILES. 45 Alphabetical by Company Name 92 Index by Country SUPPLIER PROFILES. 93 Alphabetical by Company Name

Experience of inpatients with ulcerative colitis throughout

European Association for Cardiovascular Prevention and Rehabilitation A registered branch of the European Society of Cardiology

Mediwales Finance and Funding Event:

Potential of the use of electronic patient information for clinical research in the pharmaceutical industry

Chronic Pain Management Team

Study Abroad Opportunities

Healthcare Practice. Healthcare PanelBook 2017

Access Telefonica. (Making the right connections in the post-telefonica-digital era) May 27 th - 28 th Sales lead

Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Patient survey report 2004

Dietitians-nutritionists around the World

UK Renal Registry 20th Annual Report: Appendix A The UK Renal Registry Statement of Purpose

EURAXESS Researchers in Motion

Bladder cancer Stakeholders

The future of Primary Care in Camden? Mansur Quraishi, Primary Care Programme Team Manager

How NICE clinical guidelines are developed

Evidence on the quality of medical note keeping: Guidance for use at appraisal and revalidation

Manpower Employment Outlook Survey Ireland. A Manpower Research Report

NHS England (Wessex) Clinical Senate and Strategic Networks. Accountability and Governance Arrangements

Spanish Offshoring: Growing Trends in a Globalized World

Economic Impact of the University of Edinburgh s Commercialisation Activity

Foundation in Paediatric Pharmaceutical Care 5th International Masterclass

Inspecting Informing Improving. Patient survey report Mental health survey 2005 Humber Mental Health Teaching NHS Trust

Executive Council 103rd session Málaga, Spain, 9-11 May 2016 Provisional agenda item 8(a)

M3 Global Research Overview

Leveraging Health System Status in the Specialty Pharmacy Market. Chris Lowe, PharmD, BCPS Director of Pharmacy

Improving Access to Psychological Therapies, Key Performance Indicators (IAPT KPIs) Q4 2011/12 final and Q1 2012/13 provisional

Vaccine uptake in under 19s (quality standard) Stakeholders Action on Smoking & Health (ASH) Advertising Standards Authority Advertising Standards

Official Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10

The Language Services Market: 2010

Patient survey report Outpatient Department Survey 2009 Airedale NHS Trust

HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery

Foundation in Paediatric Pharmaceutical Care 6th International Masterclass

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

International Recruitment Solutions. Company profile >

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

The Language Services Market: 2013

Building Our Industrial Strategy Response to Government s Industrial Strategy Green Paper. from Alzheimer s Research UK

Northern Ireland Practice and Education Council for Nursing and Midwifery

Paediatric Pharmaceutical Care: Internships and Placements

Internal Audit Resources

iward SRP Innovating Nursing Care and Patient Experience

Presentation

HEALTH CARE MIDDLE EAST AND NORTH AFRICA Innovation powering health care delivery

Call for organisations to cooperate with EIT Health as EIT Health Hubs within the EIT Regional Innovation Scheme 2018

Q Manpower. Employment Outlook Survey Global. A Manpower Research Report

JOB VACANCY AT EIT FOOD / CLC North-West

Health Workforce Policies in OECD Countries

Manpower Employment Outlook Survey India. A Manpower Research Report

Pediatric Nursing. Neonatal & Neonatal Nursing Theme: Explore the Advances in Neonatal and Pediatric Nursing. 29 th International Conference on

Transcription:

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION) Feedback from 58 Latin-American patient groups PUBLISHED JUNE 2016

Que las Compañias Farmacéuticas tengan relación directa o indirectamente con mi organizacion, ayudando a la ONG para ayudar a los pacientes de poco o sin recursos. National Argentina-based patient group specialising in hepatitis and HIV/AIDS in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic-region reports (in addition to this current latam report): europe-wide I eastern europe I germany I global I italy I nordic I spain I uk I usa (10 reports)

CONTENTS ABOUT THIS REPORT Page 1 WHAT DID PATIENT GROUPS IN LATIN AMERICA SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings in Latin America Page 3 SOME POINTS ABOUT THE LATIN-AMERICAN CORPORATE RANKINGS Page 6 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 7 A FEW COMMENTS FROM PATIENT GROUPS IN LATIN AMERICA, 2015 Page 8 CASE STUDY: PATIENT-GROUP RELATIONS AND PATIENT CENTRICITY AT AbbVie Mexico Page 9 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 11 QUESTIONNAIRE FOR PHARMA COMPANIES 2015 Page 12 APPENDIX 1: Data on how patient groups in Latin America see the pharmaceutical industry in 2015 APPENDIX 2: Rankings of the 13 pharma companies for each of the 6 indicators of corporate reputation, as perceived by patient groups in Latin America in 2015 APPENDIX 3: Profiles of the 13 companies Page 13 Page 18 Page 27 APPENDIX 4: Profiles of the 58 respondent patient groups Page 42

LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF PATIENT GROUPS IN LATIN AMERICA Percentage of patient groups in Latin America claiming familiarity with the company Page 2 Percentage of patient groups in Latin America claiming familiarity, and which also worked with the company Page 2 % of patient groups (by geographic region) stating that pharma is Excellent or Good at BEING INNOVATIVE Page 4 % of patient groups (by geographic region) stating that pharma is Excellent or Good at PROVIDING SERVICES TO PATIENTS OUTSIDE ITS BUSINESS REMIT Page 4 % of patient groups (by geographic region) stating that pharma is Excellent or Good at BEING TRANSPARENT IN ALL CORPORATE ACTIVITIES Page 4 Average scores for each of the six indicators of corporate reputation in 2015, according to patient groups based in Latin America, v. worldwide Page 6 The corporate reputation of pharma companies in 2015, according to patient groups based in Latin America, v. worldwide If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 6 Page 7 Page 14 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 15 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups in Latin America)? Pages 16-17 Companies with the most effective patient-centred strategy (rankings of 13 companies, 2015) Page 19 Companies providing the best high-quality patient information (rankings of 13 companies, 2015) Page 20 Companies with the best record on patient safety (rankings of 13 companies, 2015) Page 21 Companies with the most-useful high-quality products (rankings of 13 companies, 2015) Page 22 Companies with the best record of transparency (rankings of 13 companies, 2015) Page 23 Companies with the best record on integrity (rankings of 13 companies, 2015) Page 24 Rankings of the 13 pharmaceutical companies in 2015, ALPHABETIC ORDER Page 25 Rankings of the 13 pharmaceutical companies in 2015, HIGHEST TO LOWEST Page 26 Profile of 2015 s 58 respondent patient groups based in Latin America by therapy area Page 43 Profile of 2015 s 58 respondent patient groups based in Latin America by country Page 43 Geographic remit of 2015 s 58 respondent Latin-American patient groups Page 44

LIST OF TABLES AND CHARTS CONTINUED AbbVie page 45 AstraZeneca page 51 Bayer page 53 Boehringer Ingelheim page 55 B-MS page 56 Eli Lilly page 60 GSK page 65 Janssen page 68 Merck & Co (US) page 72 Novartis page 75 Pfizer page 79 Roche page 80 Sanofi page 82 profiles of the 13 companies, according to the patient groups in latin america familiar with these companies, or have worked with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the patient groups in Latin America familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the patient groups in Latin America that have worked with the company. How the profiled company performed in Latin America for different therapy areas, compared with the company s averages in Latin America across all therapy areas in 2015. How the profiled company performed in Latin America for different countries/regions, compared with the company s averages in Latin America in 2015. how the company ranks for corporate reputation compared with other companies The profiled company s rankings in Latin America in 2015 for the six indicators of corporate reputation, compared with 12 other companies The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The therapy areas and countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson

Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0)1547-520-965 E-mail: info@patient-view.com Registered in England, number: 3944382 Data protection registration number: Z7133076 VAT registration number: GB-760-985-885 Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.